INTRODUCTION
Systemic sclerosis (Ssc) is an autoimmune disease characterized by cutaneous and visceral fibrosis. Its pathogenesis is incompletely understood and efforts are made in order to better define implication of the immune system. T helper (Th) cells are key regulators of the immune response and they seem to be involved in Ssc clinical manifestations [1] . There are mainly three subclasses of Th cells that were demonstrated to be involved in autoimmunity: Th1, Th2 and Th17. Th1 secretes mainly IFN-γ .Th2 secretes IL-4, IL-5, IL-6 and IL-13. Th17 secretes mainly IL-17A and IL-17F [2] . Th 17 cells have already been demonstrated to be involved in various autoimmune diseases like rheumatoid arthritis [3] and systemic lupus erythematosus [4, 5] . Th1 and Th2 have already been demonstrated to be involved in Ssc pathogenesis via dermal fibroblasts [6] .
Therefore, the aim of the study is to determine key cytokines secreted by Th1 (IFN-γ), Th2 and Th17 (IL-17) in Ssc patients and correlate them with specific manifestations of Ssc patients.
MATERIALS AND METHODS

SYSTEMIC SCLEROSIS PATIENTS AND CONTROLS
35 consecutive patients (32 females, 3 males, 55.60 ± 11.6 years) and 20 age and sex matched controls (18 females, 2 males, 52 ± 14.5 years) from "Colentina" Clinical Hospital (Internal Medicine Clinic) between January 2013 and December 2014 were enrolled. Ssc patients were diagnosed according to the classification criteria proposed by the American College of Rheumatology (ACR) [7] . All patients were clinically examined and evaluated for visceral involvement. Interstitial lung disease was evaluated with chest radiography and high resolution CT. Respiratory function tests (flow spirometry and diffusing capacity for carbon monoxide-DLCO) were performed. Pulmonary hypertension was determined indirectly by trans-thoracic echocardiography (values above 35 mm Hg) [8] . Cutaneous involvement was determined in all patients by assessing presence/absence and frequency of Raynaud's phenomenon, calculation of modified Rodnan skin score [9] , presence/absence assessment of telangiectasias, presence/absence of ischemic digital ulcers (defined by loss in ephitelialisation and tissue that involved subcutaneous tissue), presence/absence of calcinosis (defined by calcium deposits in soft tissues that were visible and confirmed by the x-ray) [10] . Frequency of Raynaud's phenomenon was defined as daily or less frequent. Disease activity score was assessed using European League Against Rheumatism (EULAR) Scleroderma Trial and Research group criteria (EUSTAR criteria) [11] . In Ssc patients, erythrocyte sedimentation rate and C reactive protein levels were determined. Also therapy that had already been initiated in Ssc patients was recorded at the moment of blood sampling. All patients and controls signed an informed consent according to the Declaration of Helsinki and the study was approved by the local ethics committee.
SERUM CYTOKINE ANALYSIS IN PATIENTS AND CONTROLS
Blood samples were centrifuged for 20 minutes at 4000 rpm and the serum stored at -80°C for further analysis. Antinuclear antibodies (ANA) were detected by indirect immunofluorescence. Commercial enzyme linked immunosorbent assay (ELISA) kits were used according to manufacurer's instruction to determine anti-Scl70 and anti-centromere antibodies (Euro Diagnostica, Malmo, Sweden). IL-17, IL-6 and IFN-γ levels were determined using commercial ELISA kits according to manufacturers' instructions (R&D Systems, Minneapolis, USA). All samples were evaluated in duplicate. Mean optical density at 450 nm read on a plate reader (BioRad Hercules, CA, SUA) was determined for each sample.
STATISTICAL ANALYSIS
Continuous variables were presented as mean ± standard deviation if they were normally distributed or as median and minimum and maximum value if they were non-normally distributed. To test normality of the continuous variables, Kolmogorov-Smirnov tests were applied. Fischer's exact tests were used to determine whether two categorical variables are associated. Difference in serum concentration markers among groups was performed using MannWhitney U test. Spearman's rank correlation coefficient was used in order to assess a linear relationship among the continuous variables. Logistic regression was used to compare serum cytokine levels after adjustment for gender and age. A p value ≤ 0.05 was considered significant. Statistical analysis was performed using the Statistical Software for Social Sciences (SPSS), Version 16 for Windows (Chicago, USA).
RESULTS
35 Ssc patients and 20 age and sex-matched controls were recruited. Data about patients are summarized in Table 1 . Serum IL-17 and IL-6 levels were not significantly different in Ssc patients and controls (IL-17 median value for SSc patients: 0 pg/mL minimum 0 pg/ml-maximum 18.4 pg/mL versus controls median value 0 pg/mL minimum 0 pg/mL maximum 1.41 pg/mL, Figure 1 and IL-6 median value for Ssc patients 1.15 pg/mL, minimum 0.73 pg/mL-maximum 2.70 pg/mL versus median value for serum IL-6 in controls 1.25 pg/ mL, minimum 1.11 pg/mL maximum 1.46 pg/mL, Figure 2 ). However, serum IFN-γ levels were higher in Ssc patients when compared to controls (IFN-γ for SSc patients: 3.68 pg/mL minimum 0 pg/ ml-maximum 17.60 pg/mL versus controls median value 0.64 pg/mL minimum 0 pg/mL maximum 4.76 pg/mL, Figure 3 ). When associating clinical manifestations within the Ssc group with serum cytokine levels, patients with digital ulcers had lower IL-6 levels compared to patients without digital ulcers (median IL-6 levels 0.92 pg/mL, minimum 0.76 pg/mL-maximum 1.71 pg/mL versus median 1.30 pg/mL minimum 0.73 pg/mL-maximum 2.70 pg/mL, p = 0.03, Mann Whitney U test). Patients with telangectasia had higher serum IL-17 levels compared to patients without telangiectasia (median 2.12 pg/mL minimum 0 pg/mL-maximum 18.43 pg/mL versus median 0 pg/mL minimum 0 pg/mL maximum 18.43 pg/mL, p = 0.023, Mann whitney U test). Patients with calcinosis also had lower serum IL-6 levels compared to patients without (median IL-6 levels 0.96 pg/mL minimum 0.73 pg/mL-maximum 1.71 pg/mL versus median 1.25 pg/mL minimum 0.76 pg/mL-maximum 2.70 pg/mL, p = 0.046, Mann Whitney U test). Patients with pulmonary hypertension also had higher IFN-γ levels compared to Ssc patients without pulmonary hypertension (median IFN-γ levels 8.80 pg/mL minimum 5.2 pg/mLmaximum 17.6 pg/mL versus median 3.03 pg/mL minimum 0 pg/mL maximum 9.96 pg/mL, p < 0.001, Mann Whitney U test). Interestingly, patients with active disease (EUSTAR score ≥3) had higher IL-17 serum levels compared to Ssc patients with inactive disease (median IL-17 levels 1.41 pg/mL minimum 0 pg/mL-maximum 18.43 pg/mL versus median 0 pg/mL minimum 0 pg/mL-maximum 5.67 pg/mL).
After performing logistic regression to control for age and gender of Ssc patients, IL-17 levels remained independently associated with clinical manifestations of Ssc patients (telangiectasia and active systemic sclerosis, Table 2) .
DLCO values negatively correlated with IFN-γ levels (r = -0.57, p=0.001) and values of the mean pulmonary artery pressure positively correlated with levels of IFN-γ (r = 0.48, p = 0.006). 
DISCUSSION
Only serum levels of IFN-γ were higher in Ssc patients compared to controls. However, IL-17 serum levels independently associated with higher disease activity scores and presence of telangiectasia. Data about IL-17 levels in Ssc patients are conflicting in the literature. On the one hand there are studies that demonstrate that serum IL-17 were lower in Ssc patients compared to controls [12] and, on the other hand, there are reports about higher IL-17 levels in Ssc patients [13] . In this study there was no statistically significant difference between Ssc patients and controls. However, it was shown that IL-17 levels would differentiate subsets of disease (more active disease, patients with telangiectasia). In addition, recent reports suggested that Th17 cells are present in Ssc skin and associated with modified Rodnan skin score [14] . In this study there was no correlation between serum IL-17 levels and modified Rodnan skin score and therefore IL-17 is not a potential biomarker for skin score assessment. This is most probably due to the polymorphic aspects of Ssc disease and multiple visceral involvements, with multiple sources for IL-17 synthesis. There were no differences in serum IL-6, IFN-γ and IL-17 between diffuse and localized subsets of Ssc. Given all this growing body of evidence, it is more and more clear that Ssc is also a Th17 mediated disease as its main cytokine is implicated in more severe Ssc forms.
Even if lower IL-6 levels did associate in univariate analysis with calcinosis and digital ulcers, IL-6 did not remain independently associated with these clinical features when adjusting to age and gender. Levels of IL-6 were relatively low, and one possible explanation is that most patients were already treated with steroids. Other studies demonstrated that serum levels of IL-6 were upregulated in Ssc patients [15] and correlated with pulmonary disease and pulmonary hypertension.
IFN-γ levels were higher in patients with arterial pulmonary hypertension and positively correlated with mean systolic pulmonary arterial pressure and negatively correlated with DLCO. These findings suggest that Th1 cell driven response is involved in pulmonary manifestations of Ssc. A previous study discussed about classification of Ssc diseases subset with the aid of Th17 cells and IFN-γ. The study suggested that limited subtype of disease is associated with high expression of IL-17 and IFN-γ [16] . In the present study, IL-17 and IFN-γ clustered a group of patients that had a higher disease activity score and pulmonary hypertension. Therefore, by simultaneously assessing IL-17 and IFN-γ, one could identify patients with high clinical score and pulmonary hypertension. It is more and more obvious that multiple cytokines need to be measured in Ssc patients in order to better define disease subgroups.
CONCLUSION
Th17 and Th1 cell responses are active in Ssc patients as their cytokines associated with higher disease activity scores and pulmonary manifestations. Th17 and Th1 specific activity and homing within Ssc patients still needs to be defined and determined in order to target them as potential future therapeutic targets.
